RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Bristol-Myers Squibb (NYSE: BMY) put an early stop to its China Phase III trial of Opdivo (nivolumab), because of positive results. Opdivo is a PD-1 inhibitor and was being tested as a second-line treatment for non-small cell lung cancer. The trial’s data monitoring committee determined Opdivo was superior to docetaxel. Using results from the trial, BMS submitted a BLA to the CFDA for Opdivo, and, according to BMS, Opdivo is the first immuno-oncology therapy for second-line NSCLC to be accepted for review in China.
Source: China Biotoday
